title: Non-alcoholic Fatty Liver Disease (NAFLD)--A Review.
abstract: Non-alcoholic fatty liver disease (NAFLD) is an emerging problem in Hepatology clinics. It is closely related to the increased frequency of overweight or obesity. It has recognised association with metabolic syndrome. Central obesity, diabetes mellitus, dyslipidemia are commonest risk factors. Association with hepatitis C genotype 3 is also recognised. NAFLD is an important cause of cyptogenic cirrhosis of liver. It affects all populations and all age groups. Most patients with NAFLD are asymptomatic or vague upper abdominal pain. Liver function tests are mostly normal or mild elevation of aminotranferases. Histological features almost identical to those of alcohol-induced liver damage and can range from mild steatosis to cirrhosis. Two hit hypothesis is prevailing theory for the development of NAFLD. Diagnosis is usually made by imaging tools like ultrasonogram which reveal a bright liver while liver biopsy is gold standard for diagnosis as well as differentiating simple fatty liver and non-alcoholic steatohepatitis (NASH). Prognosis is variable. Simple hepatic steatosis generally has a benign long-term prognosis. However, one to two third of NASH progress to fibrosis or cirrhosis and may have a similar prognosis as cirrhosis from other liver diseases. Treatment is mostly control of underlying disorders and dietary advice, exercise, insulin sensitizers, antioxidants, or cytoprotective agents. The prevalence of NAFLD is increasing. So it needs more research to address this problem.
authors.affiliation: Dr Md Fazal Karim, Associate Professor, Department of Hepatology, Sir Salimullah Medical College & Mitford Hospital, Dhaka, Bangladesh; E-mail: drfazalkarim@gmail.com.
authors.forename: M F
authors.initials: MF
authors.lastname: Karim
authors.forename: M
authors.initials: M
authors.lastname: Al-Mahtab
authors.forename: S
authors.initials: S
authors.lastname: Rahman
authors.forename: C R
authors.initials: CR
authors.lastname: Debnath
mesh_terms: D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D011379:Prognosis; D012307:Risk Factors